Asked what this has to do with the pivotal trial and got this response.
Thank you for your enquiry. Our commercialisation strategy to date has predominantly focused on the US market. Study NCT06510855 will further our commercialisation plans in Europe in addition to providing additional data to support the premarket application (PMA) to the FDA for both aortic stenosis and a potential secondary indication in valve-in-valve patients.
- Forums
- ASX - By Stock
- AVR
- Clinical trials
Clinical trials, page-19
-
- There are more pages in this discussion • 18 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVR (ASX) to my watchlist
|
|||||
Last
$13.00 |
Change
1.100(9.24%) |
Mkt cap ! $274.7M |
Open | High | Low | Value | Volume |
$12.00 | $13.20 | $12.00 | $718.4K | 56.70K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 680 | $13.00 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$13.25 | 1000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 1449 | 13.000 |
1 | 1000 | 12.950 |
1 | 350 | 12.930 |
1 | 1000 | 12.920 |
1 | 7 | 12.900 |
Price($) | Vol. | No. |
---|---|---|
13.200 | 15 | 1 |
13.250 | 1000 | 1 |
13.300 | 3 | 1 |
13.350 | 8 | 1 |
13.400 | 525 | 1 |
Last trade - 16.10pm 11/09/2024 (20 minute delay) ? |
Featured News
AVR (ASX) Chart |